KEVIN GAREY to Diarrhea
This is a "connection" page, showing publications KEVIN GAREY has written about Diarrhea.
Connection Strength
3.239
-
Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul; 93(3):286-9.
Score: 0.455
-
Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. Drugs Today (Barc). 2013 Apr; 49(4):239-52.
Score: 0.368
-
Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012 Feb; 6(1):17-23.
Score: 0.340
-
Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010 May; 44(5):878-84.
Score: 0.300
-
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009 Jan; 43(1):91-3.
Score: 0.274
-
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008 Jun; 42(6):827-35.
Score: 0.261
-
Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother. 2006 Jun; 40(6):1030-4.
Score: 0.228
-
Stool Interleukin-1? Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea. Clin Infect Dis. 2023 02 08; 76(3):e1467-e1475.
Score: 0.182
-
Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
Score: 0.138
-
Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
Score: 0.135
-
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec; 66(12):2850-5.
Score: 0.083
-
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul; 8(7):747-60.
Score: 0.076
-
In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010 Apr; 63(4):355-8.
Score: 0.075
-
Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010 Apr; 74(4):309-18.
Score: 0.074
-
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):964-8.
Score: 0.062
-
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006 May; 101(5):1112-6.
Score: 0.057
-
A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains. Microb Genom. 2021 06; 7(6).
Score: 0.041
-
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 03 19; 66(7):e1-e48.
Score: 0.032
-
Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug; 48(2):137-43.
Score: 0.029
-
New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis. 2008 Oct; 21(5):500-7.
Score: 0.017
-
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005 Apr; 3(2):201-11.
Score: 0.013